GlassScriptPhysician profile
Christopher F Killen
NPI 1083950885
$5,131.90
in general payments reported to CMS, 2019-2025
29 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $910 · 2022: $854 · 2023: $1,601 · 2024: $1,400 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,246 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,246.07 |
| Education | $122.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $950.74 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $825.01 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $462.19 | 2021-2024 | Jardiance, Mounjaro, Trulicity |
| Xeris Pharmaceuticals, INC. | $335.73 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.03 | 2023-2024 | Jardiance |
| Amgen INC. | $240.39 | 2021-2024 | Evenity, Prolia, Tepezza |
| Alexion Pharmaceuticals, INC. | $187.14 | 2021-2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $177.57 | 2022-2024 | |
| Medtronic, INC. | $177.04 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Astellas Pharma US INC | $172.61 | 2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $167.95 | 2021-2022 | |
| Corcept Therapeutics | $144.08 | 2022-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $129.14 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $116.47 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $105.08 | 2021-2024 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $90.20 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $89.08 | 2021-2024 | Isturisa, Signifor Lar |
| Chiasma, INC. | $70.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $66.42 | 2022-2023 | |
| Radius Health, INC. | $65.90 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $62.73 | 2022 | |
| Horizon Therapeutics Plc | $44.45 | 2023 | Tepezza |
| Eusa Pharma (US) LLC | $40.35 | 2022 | |
| Zealand Pharma US, INC. | $37.09 | 2021-2022 | |
| Esperion Therapeutics, INC. | $30.00 | 2022 | |
| Kyowa Kirin, INC. | $20.63 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $20.13 | 2021 | |
| Lifescan, INC. | $15.33 | 2021 | |
| Echosens North America, INC. | $13.78 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Killen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.